Rebiotix launches late-stage superbug trial for microbiome-based drug

Rebiotix isn’t a traditional drugmaker. Its products are alive.

The 32-person company, based in Roseville, Minn., is developing a microbiome-based therapy to prevent recurrent Clostridium difficile infection. Its Microbiota Restoration Therapy, which is delivered via enema, is designed to supply a patient’s intestinal tract with an array of healthy, human-derived microbes.

Get the full story at our sister site, Drug Delivery Business News.

The post Rebiotix launches late-stage superbug trial for microbiome-based drug appeared first on MassDevice.

from MassDevice http://ift.tt/2wExCIo